Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

SF1126, a Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequence Specific Synergy When Combined with Bortezomib in Multiple Myeloma Cells

Ebenezer David, PhD, Xiaodong Peng, PhD, Benjamin G Barwick, Jonathan L Kaufman, MD, Joseph R Garlich, PhD, Sagar Lonial, MD

Blood (2008) 112 (11): 5167.

https://doi.org/10.1182/blood.V112.11.5167.5167

Published: 2008

Journal Articles

Unlike Inactivating PTEN Mutations, Pharmacological Inhibition of PTEN Does Not Increase the Sensitivity of Multiple Myeloma Cells to Inhibition of the PI3K/Akt/mTOR Pathway.

Xiaojing Wang, PhD, Shuhong Zhang, Ph.D, Xiaodong Peng, Ph.D, Joe Garlich, Ph.D, Li Chen, MD, Jing Liang, MD, Sherif Shafik Farag, MD, Ph.D

Blood (2007) 110 (11): 4785.

https://doi.org/10.1182/blood.V110.11.4785.4785

Published: 2007

Journal Articles

A Vascular Targeted Pan PI-3 Kinase Inhibitor, SF1126 with Activity Against Multiple Myeloma In Vivo .

Pradip De, PhD, Qiong Peng, PhD, Nandini Dey, MD, Breanne McDermitt, MD, Xiaodong Peng, PhD, Joseph Garlich, PhD, Sagar Lonial, MD, Donald L. Durden, MD, PhD

Blood (2006) 108 (11): 244.

https://doi.org/10.1182/blood.V108.11.244.244

Published: 2006

Journal Articles

SHP-1 regulates Fcγ receptor–mediated phagocytosis and the activation of RAC

Anita M. Kant, Pradip De, Xiaodong Peng, Taolin Yi, David J. Rawlings, Jong Suk Kim, Donald L. Durden

Blood (2002) 100 (5): 1852–1859.

https://doi.org/10.1182/blood.V100.5.1852.h81702001852_1852_1859

Published: 2002

Journal Articles

PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac

Jong Suk Kim, Xiaodong Peng, Pradip K. De, Robert L. Geahlen, Donald L. Durden

Blood (2002) 99 (2): 694–697.

https://doi.org/10.1182/blood.V99.2.694

Published: 2002

NARROW

SF1126, a Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequence Specific Synergy When Combined with Bortezomib in Multiple Myeloma Cells

Unlike Inactivating PTEN Mutations, Pharmacological Inhibition of PTEN Does Not Increase the Sensitivity of Multiple Myeloma Cells to Inhibition of the PI3K/Akt/mTOR Pathway.

A Vascular Targeted Pan PI-3 Kinase Inhibitor, SF1126 with Activity Against Multiple Myeloma In Vivo .

SHP-1 regulates Fcγ receptor–mediated phagocytosis and the activation of RAC

PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac

Email alerts

ASH Publications

American Society of Hematology

SF1126, a Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequence Specific Synergy When Combined with Bortezomib in Multiple Myeloma Cells

Unlike Inactivating PTEN Mutations, Pharmacological Inhibition of PTEN Does Not Increase the Sensitivity of Multiple Myeloma Cells to Inhibition of the PI3K/Akt/mTOR Pathway.

A Vascular Targeted Pan PI-3 Kinase Inhibitor, SF1126 with Activity Against Multiple Myeloma In Vivo .

SHP-1 regulates Fcγ receptor–mediated phagocytosis and the activation of RAC

PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only